---
title: "Scholar Rock Holding Corporation Stock 12‑Month Price Target Raised to $60.07, Implies 6% Upside"
type: "News"
locale: "en"
url: "https://longbridge.com/en/news/292011672.md"
description: "Scholar Rock Holding Corporation's average 12-month price target has been raised to $60.07 by 15 analysts, up from $59.31, implying a 6% upside based on the July 7 closing price. The consensus rating remains 'Buy' across all 17 covering analysts, with no holds or sells."
datetime: "2026-07-08T04:20:08.000Z"
locales:
  - [zh-CN](https://longbridge.com/zh-CN/news/292011672.md)
  - [en](https://longbridge.com/en/news/292011672.md)
  - [zh-HK](https://longbridge.com/zh-HK/news/292011672.md)
---

# Scholar Rock Holding Corporation Stock 12‑Month Price Target Raised to $60.07, Implies 6% Upside

-   According to estimates from 15 analysts, Scholar Rock Holding Corporation stock's average price target has risen from $59.31 to $60.07, with forecasts ranging from $55 to $70 per share
-   Based on the Jul. 7 closing price, the updated target implies approximately 6% potential upside
-   Consensus rating remains at “Buy” across 17 covering analysts, with 17 Buys, 0 Holds and 0 Sells

Explore more price target data and ratings for Scholar Rock Holding Corporation on the , and track all previous and future analyst recommendations for Scholar Rock Holding Corporation in the dedicated News Flow.

**Disclaimer**

Select reference data provided by FactSet. Copyright © 2026 FactSet Research Systems Inc. This information is not a recommendation for what you should do personally and does not constitute investment advice.

### Related Stocks

- [SRRK.US](https://longbridge.com/en/quote/SRRK.US.md)
- [FDS.US](https://longbridge.com/en/quote/FDS.US.md)

## Related News & Research

- [Scholar Rock files for up to $200 million at-the-market stock offering](https://longbridge.com/en/news/295109643.md)
- [SRRK: FDA decision for apitegromab in SMA expected by September 30, with launch readiness assured](https://longbridge.com/en/news/295698830.md)
- [Scholar Rock (NASDAQ:SRRK) Releases Earnings Results, Meets Estimates](https://longbridge.com/en/news/295175378.md)
- [Scholar Rock: Strengthened Regulatory Path and Cash Position Underscore Attractive Risk‑Reward Ahead of Apitegromab PDUFA](https://longbridge.com/en/news/295354098.md)
- [Scholar Rock Overcomes Manufacturing Hurdle to Keep Lead Drug FDA Review on Schedule](https://longbridge.com/en/news/295429730.md)